These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20169511)

  • 1. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
    Meijer P; Verbruggen B
    Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.
    Favaloro EJ; Bonar R; Kershaw G; Duncan E; Sioufi J; Marsden K
    Semin Thromb Hemost; 2009 Nov; 35(8):794-805. PubMed ID: 20169516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G; Jayakodi D; Dunkley S
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
    Favaloro EJ; Bonar R; Kershaw G; Mohammed S; Duncan E; Marsden K;
    Haemophilia; 2010 Jul; 16(4):662-70. PubMed ID: 20070382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E; Collecutt M; Street A
    Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Notes on laboratory coagulation testing for acquired hemophilia A].
    Amano K
    Rinsho Byori; 2009 Oct; 57(10):999-1003. PubMed ID: 19928498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII inhibitors: a 50-year perspective.
    Green D
    Haemophilia; 2011 Nov; 17(6):831-8. PubMed ID: 21592257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External quality assessment of factor VIII inhibitor assays.
    Bonar RA; Favaloro EJ; Marsden K
    Semin Thromb Hemost; 2013 Apr; 39(3):320-6. PubMed ID: 23436565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B; Novakova I; Wessels H; Boezeman J; van den Berg M; Mauser-Bunschoten E
    Thromb Haemost; 1995 Feb; 73(2):247-51. PubMed ID: 7792738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
    Torita S; Suehisa E; Kawasaki T; Toku M; Takeo E; Tomiyama Y; Nishida S; Hidaka Y
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):185-9. PubMed ID: 21245748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
    Kitchen S; Jennings I; Preston FE; Kitchen DP; Woods TA; Walker ID
    Semin Thromb Hemost; 2009 Nov; 35(8):778-85. PubMed ID: 20169514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.